Structure-Activity Relationships of a Series of Analogues of the RFamide-Related Peptide 26RFa

被引:33
作者
Le Marec, Olivier [1 ]
Neveu, Cindy [1 ]
Lefranc, Benjamin [1 ]
Dubessy, Christophe [1 ]
Boutin, Jean A. [2 ]
Do-Rego, Jean-Claude [3 ]
Costentin, Jean [3 ]
Tonon, Marie-Christine [1 ]
Tena-Sempere, Manuel [4 ,5 ]
Vaudry, Hubert [1 ]
Leprince, Jerome [1 ]
机构
[1] Univ Rouen, INSERM U982, Lab Neuronal & Neuroendocrine Differentiat & Comm, European Inst Peptide Res IFRMP 23,Cell Imaging P, F-76821 Mont St Aignan, France
[2] IdRS, F-78290 Croissy Sur Seine, France
[3] Univ Rouen, Lab Expt Neuropsychopharmacol, IFRMP 23, F-76183 Rouen, France
[4] Univ Cordoba, Dept Cell Biol Physiol & Immunol, E-14004 Cordoba, Spain
[5] CIBER Fisiopatol Obesidad & Nutr, Cordoba 14004, Spain
关键词
UROTENSIN-II; HYPOTHALAMIC NEUROPEPTIDE; OREXIGENIC ACTIVITY; AMINO-ACIDS; SUBSTANCE-P; RECEPTOR; RAT; IDENTIFICATION; LIGAND; HORMONE;
D O I
10.1021/jm200418c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
26RFa is a new member of the RFamide peptide family that has been identified as the endogenous ligand of the orphan GPCR GPR103. As the C-terminal heptapeptide (26RFa((20-26))) mimics the action of the native peptide on food intake and gonadotropin secretion in rodents, we have synthesized a series of analogues of 26RFa((20-26)) and measured their potency to induce [Ca(2+)](i) mobilization in G alpha(16)-hGPR103-transfected CHO cells. Systematic replacement of each residue by an alanine (Ala scan) and its D-enantiomer (D scan) showed that the last three C-terminal residues were very sensitive to the substitutions while position 23 tolerated rather well both modifications. Most importantly, replacement of Ser(23) by a norvaline led to an analogue, [Nva(23)]26RFa((20-26)), that was 3-fold more potent than the native heptapeptide. These new pharmacological data, by providing the first information regarding the structure-activity relationships of 26RFa analogues, should prove useful for the rational design of potent GPR103 receptor ligands with potential therapeutic application.
引用
收藏
页码:4806 / 4814
页数:9
相关论文
共 41 条
[1]   ACE revisited: A new target for structure-based drug design [J].
Acharya, KR ;
Sturrock, ED ;
Riordan, JF ;
Ehlers, MRW .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (11) :891-902
[2]   CONFORMATIONAL PROPERTIES OF L-LEUCINE, L-ISOLEUCINE, AND L-NORLEUCINE SIDE-CHAINS IN L-LYSINE COPOLYMERS [J].
ARFMANN, HA ;
LABITZKE, R ;
WAGNER, KG .
BIOPOLYMERS, 1977, 16 (08) :1815-1826
[3]   The G-protein-coupled receptor GPR103 regulates bone formation [J].
Baribault, H ;
Danao, J ;
Gupte, J ;
Yang, L ;
Sun, BH ;
Richards, W ;
Tian, H .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (02) :709-717
[4]   Novel stable PACAP analogs with potent activity towards the PAC1 receptor [J].
Bourgault, Steve ;
Vaudry, David ;
Botia, Beatrice ;
Couvineau, Alain ;
Laburthe, Marc ;
Vaudry, Hubert ;
Fournier, Alain .
PEPTIDES, 2008, 29 (06) :919-932
[5]   Structure-activity studies on prolactin-releasing peptide (PrRP). Analogues of PrRP-(19-31)-peptide [J].
Boyle, RG ;
Downham, R ;
Ganguly, T ;
Humphries, J ;
Smith, J ;
Travers, S .
JOURNAL OF PEPTIDE SCIENCE, 2005, 11 (03) :161-165
[6]   Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat [J].
Bruzzone, Federica ;
Lectez, Benoit ;
Alexandre, David ;
Jegou, Sylvie ;
Mounien, Lourdes ;
Tollemer, Helene ;
Chatenet, David ;
Leprince, Jerome ;
Vallarino, Mauro ;
Vaudry, Hubert ;
Chartrel, Nicolas .
JOURNAL OF COMPARATIVE NEUROLOGY, 2007, 503 (04) :573-591
[7]   Anatomical distribution and biochemical characterization of the novel RFamide peptide 26RFa in the human hypothalamus and spinal cord [J].
Bruzzone, Federica ;
Lectez, Benoit ;
Tollemer, Helene ;
Leprince, Jerome ;
Dujardin, Cynthia ;
Rachidi, Walid ;
Chatenet, David ;
Baroncini, Marc ;
Beauvillain, Jean-Claude ;
Vallarino, Mauro ;
Vaudry, Hubert ;
Chartrel, Nicolas .
JOURNAL OF NEUROCHEMISTRY, 2006, 99 (02) :616-627
[8]  
CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096
[9]   Identification of 26RFa, a hypothalamic neuropeptide of the RFamide peptide family with orexigenic activity [J].
Chartrel, N ;
Dujardin, C ;
Anouar, Y ;
Leprince, J ;
Decker, A ;
Clerens, S ;
Do-Régo, JC ;
Vandesande, F ;
Llorens-Cortes, C ;
Costentin, J ;
Beauvillain, JC ;
Vaudry, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (25) :15247-15252
[10]  
Chartrel N, 2006, HANDBOOK OF BIOLOGICALLY ACTIVE PEPTIDES, P779, DOI 10.1016/B978-012369442-3/50110-0